• Submitted by: admin
• Health and Medicine
• 05 / 20 / 2010

---

HAVANA, Cuba, May 19 (acn) Over 10,000 patients from over a dozen countries, including Cuba, have been benefited from Heberprot-P, a medicament developed on the island and world leader for the treatment of diabetic foot ulcers.

In an exclusive interview with ACN, Doctor Hector Alvarez, director of the Institute of Angiology and Vascular Surgery, highlighted that this drug favors the closing of lesions and a decrease in the number of amputations in most cases.

Venezuela, Argentina, Mexico, the Dominican Republic, Serbia, Libya, Tunisia and Algeria are among the countries using Heberprot-P, developed at Havana’s Center for Genetic Engineering and Biotechnology, he underlined.

Doctor Alvarez announced that a national program will soon begin Algeria, for which a group of Cuban experts will travel to that country.

Some 3,000 of the 10,000 patients benefited from this medicine are Cubans, stressed Alvarez, who is also the vice-president of the organizing committee of the 9th Caribbean Congress on Angiology and Vascular Surgery, Angiocaribe 2010, underway at Havana’s Convention Center.

The spread of Heberprot-P is one of the nation’s outstanding scientific results of 2009 in the fields of biotechnology and pharmaceutical products, along with vaccines against various diseases, new formulations of Alfa and Gamma interferon, monoclonal antibodies and other products.
 
At a world level, diabetic foot lesions are health problems, and it’s estimated that by 2025 there will be some 300 million people suffering from this chronic disease, responsible for a high number of deaths and a high percentage of amputations.

Source: ACN